Shamburg News · 8-K filed Nov 5, 2026, 4:01 PM EST

BridgeBio Oncology Therapeutics' Chief Medical and Development Officer to resign

BBOT · BridgeBio Oncology Therapeutics, Inc.

  • Leadership change
  • Materiality: high

On October 30, 2026, Yong Ben, M.D., M.B.A. gave notice of his resignation as Chief Medical and Development Officer of BridgeBio Oncology Therapeutics, Inc., effective January 8, 2027. The filing states the resignation was not due to any disagreement with the Company regarding its operations, policies or practices.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 5.02, accession 0001193125-26-449722.

Written from the filing by Shamburg Markets. Figures are as reported by the company.